Literature DB >> 12681164

[Questionnaire for patients with ischaemic cardiopathy on their reaction to various alarm symptoms].

J López de la Iglesia1, E Martínez Ramos, L Pardo Franco, S Escudero Alvarez, R I Cañón de la Parra, M T Costas Mira.   

Abstract

OBJECTIVES: To find the degree of information that patients with ischaemic cardiopathy (IC) possess and their behaviour on alarm symptoms (thoracic pain of ischaemic profile under stress, at rest, worsening under stress and for over 20'), how they manage sub-lingual nitro-glycerine (SLNTG), and the source of their information.
DESIGN: Transversal descriptive study based on personal interview and our own questionnaire, from September to December 2001.
SETTING: Primary Care. Six clinics in three urban Health Areas.Participants. Randomised sample of 98 patients with IC (stable angina, unstable angina, angina with infarct). MEASUREMENTS AND
RESULTS: 93 people (57 male, 36 women) were surveyed. Their average age was 71 19.34 had diagnosis of infarct. 17.2% (95% CI, 9.5%24.9%) had no SLNTG available. 78.5% (95% CI; 70.2%-86.8%) and 81.7% (95% CI; 73.8%-89.6%) of those with angina under stress or at rest, respectively, did not know when to attend the hospital Emergency department. 37.8% (95% CI, 26.8%-48.8%) with steady stress angina would attend a hospital or their doctor urgently. 100% of patients had received no information on angina at rest, under steady stress and for over 20'. There was no difference in behaviour before stress angina between patients who had been informed by Primary Care and those informed by Specialists. There was a difference, though, for good use of SLNTG between infarct and non-infarct patients (p = 0.003).
CONCLUSIONS: Our cardiopaths do not recognise alarm signals quickly; and so do not benefit as well as they might from hospital treatment. No doctor (Primary Care or specialist) informed them of the different ways to confront stable and unstable angina. Only a very small number used SLNTG in stress angina properly and knew when to attend Casualty. There is an urgent need to improve the health education of our cardiopaths.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681164      PMCID: PMC7679739          DOI: 10.1016/s0212-6567(03)79166-5

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  34 in total

1.  Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.

Authors:  J Pekkanen; S Linn; G Heiss; C M Suchindran; A Leon; B M Rifkind; H A Tyroler
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

2.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

3.  Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care.

Authors:  W S Leslie; A Urie; J Hooper; C E Morrison
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

4.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; J L Anderson; E M Antman; B A Braniff; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B J Riegel; R O Russell; E E Smith; W D Weaver
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

5.  [Delayed thrombolytic administration in myocardial infarction;].

Authors:  F J Ochoa Gómez; J M Carpintero Escudero; E Ramalle-Gómara; P M Aguilar; I Saralegui Reta; V L Catón
Journal:  Med Clin (Barc)       Date:  1997-04-05       Impact factor: 1.725

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

8.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

Authors: 
Journal:  Circulation       Date:  1998-06-23       Impact factor: 29.690

9.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.